Anti-VEGF therapy with Ranibizumab is shown to be effective among DME patients with lower central retinal thickness…. 

Doubling the daily allowance of protein may protect against muscle loss during dieting and exercise related weight loss….

Grocery shopping with sleep deprivation leads to choosing foods higher in calories and with less nutritional value….

New clinical trials reveal the new SGLT2 inhibitor lowers HbA1c as well as sitagliptin…. 

Cystatin C alone, or in combination with creatinine may be a better predictor for renal disease compared to creatinine alone…. 

Negative copeptin and troponin tests may be used to rule out an acute myocardial infarction…. 

Bariatric surgery is not the only effective treatment regimen in severely obese children…. 

Excessive coffee consumption associated with an increased risk of death….

Over the past few months we have brought you the latest information on SGLT2 Inhibitors, examining this new class of drugs from every angle including how they work, prescription insurance coverage, and both clinician and patient experience with this new medication. Jansen, the manufacturer of the only approved SGLT2 Inhibitor, …

SGLT2 Inhibitors are a new class of drugs aimed at type 2 diabetes. This class of medications is based on blocking the re-uptake of glucose by the kidneys. SGLTs function to ensure that glucose entering the kidneys is returned to the bloodstream instead of being passed in the urine. SGLT-2 …